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Colorectal cancerp21-activated kinases (PAKs) were initially identiﬁed as effector proteins downstream from GTPases of the
Rho family. To date, six members of the PAK family have been discovered in mammalian cells. PAKs play im-
portant roles in growth factor signalling, cytoskeletal remodelling, gene transcription, cell proliferation and
oncogenic transformation. A large body of research has demonstrated that PAKs are up-regulated in several
human cancers, and that their overexpression is linked to tumour progression and resistance to therapy.
Structural and biochemical studies have revealed the mechanisms involved in PAK signalling, and opened
the way to the development of PAK-targeted therapies for cancer treatment. Here we summarise recent ﬁnd-
ings from biological and clinical research on the role of PAKs in gastrointestinal cancer, and discuss the cur-
rent status of PAK-targeted anticancer therapies.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Since Manser and colleagues discovered the ﬁrst member of the
family of p21-activated kinases (PAKs), PAK1, in 1994 [1], a tremendous
amount of work has revealed the roles of PAKs in diverse cellular pro-
cesses, including cytoskeletal reorganisation, gene transcription, cell
proliferation and survival, and oncogenic transformation (for reviews
see [2–4]).Members of the p21-activated kinase family are key effectors
of the Rho family of GTPases, which act as regulatory switches that con-
trol cell proliferation andmotility [3–5]. PAKs are either up-regulated or
hyper-activated in a variety of human cancers and abundant evidence
points to roles for PAKs in tumourigenesis (for reviews see [2,3]).
Here recentﬁndings regarding the biological functions of PAK signalling
in gastrointestinal cancers are summarised. The focus is on themolecu-
lar pathways activated by PAKs in the context of four gastrointestinal
cancers: hepatocellular carcinoma (HCC), pancreatic cancer, gastric
cancer and colorectal carcinoma (CRC).AP3, CDK5 kinase regulatory
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The PAK family of 6 serine/threonine kinases are classiﬁed into two
groups based on sequence, structural homology and response to activated
GTPases (Fig. 1). Both group I (PAKs 1–3) and group II (PAKs 4–6) PAKs
are characterised by an N-terminal regulatory domain and a conserved
C-terminal kinase domain [3]. Group I PAKs are approximately 70% iden-
tical in sequence overall, but share greater than 90% identity in their ki-
nase domains. There is however only approximately 50% identity
between the kinase domains of group I and II PAKs [4]. Binding of the ac-
tivated forms of the GTPases Cdc42 or Rac to the regulatory domain acti-
vates PAKs 1, 2 and 3 [6,7]. Signals from growth factor receptor tyrosine
kinases and G protein-coupled receptors lead to the activation of PAKs
via both GTPase-dependent and independent mechanisms. In particular,
oncogenic Ras often activates PAK in cancers [8].
Structural studies have revealed that group I PAKs have a kinase
domain, a p21-binding domain (PBD) and an auto-inhibitory domain
(AID) which overlaps with the PBD [9]. Binding of an activated
GTPase to a group I PAK disrupts PAK dimerisation leading to a series
of conformational changes that unfold the AID, which in turn dissoci-
ates from the catalytic domain of the other molecule in the dimer
[9–12]. All group I PAKs contain a threonine residue in their kinase
domain, and dissociation of the AID permits this threonine residue
to be autophosphorylated, which is necessary for full kinase activity
[13]. Group I PAKs also have an N-terminal domain which binds to
PIX, an important downstream effector [14]. Unlike group I PAKs,
PAKs 4–6 do not have PIX-binding domains. Like the AID in group I
PAKs, the group II PAKs 4–6 contain within their N-terminal regions
an auto-inhibitory pseudosubstrate domain (PSD), which inhibits
the kinase activity of group II PAKs in the absence of any GTPase (Fig. 1)
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PAK1 revealed plasticity of the catalytic domain of active group II PAKs,
and suggested that there are a number of possible movements allowed
within the kinase domain during catalysis [17]. Indeed, group I and
group II PAKs have distinct substrate speciﬁcities [18]. The catalytic do-
main of PAK1 has a typical kinase fold containing N- and C-terminal
lobes connected by a hinge region which forms a pocket for ATP binding
and substrate catalysis [9,19]. Although the initial search for PAK inhibi-
tors focussed on ATP competitors, because of the high degree of similarity
between the ATP-binding pockets of kinases such compounds often have
poor selectivity, and therefore cause unwanted side effects. PAK inhibitors
that target other regions of the molecule have also been developed, and
will be discussed later in this review.
3. Biological activities of PAKs
The PAK kinase family plays important roles in many biological
activities, including stimulation of cell proliferation, motility and survival
[2–4]. Deregulation of these cellular processes initiates and promotes car-
cinogenesis. PAKs stimulate cell proliferation through enhancing the acti-
vation of the MAP kinase pathway, and thereby promoting cell cycle
progression. PAK1 phosphorylates two mediators of the MAP kinase
pathway, MEK1 and Raf1 [20–22], and facilitates the activation of these
kinases by their upstream activators Raf1 and Ras, respectively. The ki-
nase activity of PAK1 peaks at entry into mitosis and remains sustained
during mitotic progression. PAKs also promote cell cycle progression by
regulation of cyclin D1 expression [23,24].
PAKs regulate cell motility by changing cytoskeletal dynamics. PAKs
function as downstream effectors of Rac/Cdc42 in the regulation of the
actin cytoskeleton and hence stimulate cell motility and invasion. Growth
factors and other cell stimuli cause the redistribution of PAK1 from the
cytoplasm into cortical actin structures and focal adhesions [25,26].
PAK1 then interacts with and phosphorylates cytoskeletal proteins, in-
cluding myosin light chain kinase [27,28], LIM-kinase [29], and the
p41-Arc subunit of the Arp2/3 complex [30], and thereby regulates
reorganisation of the cytoskeleton.
PAKs also stimulate cell survival by inhibition of apoptosis
(i.e. programmed cell death). Both PAK1 and PAK5 phosphorylate Bad,
a pro-apoptotic protein, reducing its binding to and inhibition of the
two anti-apoptotic proteins Bcl-2 and Bcl-xL, and thereby leading to
enhancement of cell survival [31–34]. PAK1 also phosphorylates BimL,
another pro-apoptotic protein, and prevents it from binding to and
inhibiting Bcl-2 [35]. In rhabdomyosarcoma PAK1 additionally phos-
phorylates the transcription factor forkhead homolog, and suppresses
its ability to activate pro-apoptotic target genes [36]. Amongst group II
PAKs, PAK4 is a key effector for Cdc42 and mediates downstream sig-
nals that control cell motility, proliferation and survival [37].
4. PAKs in cancer
The PAK kinase family has a variety of effects that promote carci-





Fig. 1. Structures of PAKs. The kinase domains of group I PAKs (PAKs 1–3) and group II PAKs
binding domain (PBD). The group I PAKs contain an auto-inhibitory domain (AID), and bind
or Cdc42 to the PBD disrupts PAK dimerisation leading to a series of conformational chan
molecule in the dimer. Dissociation of the AID permits a conserved threonine residue in th
[13]. The phosphorylation sites in the activation loop differ between individual PAKs and a
domain (PSD). Binding of activated Rac or Cdc42 to the PBD of group II PAKs causes conforsurvival, angiogenesis [38], the epithelial–mesenchymal transition
[39] and anchorage-independent growth [40,41]. PAKs enhance tu-
mour development by down-regulation of several pro-apoptotic
pathways, as discussed in the previous paragraph. The role of PAKs
in the regulation of cytoskeletal dynamics contributes signiﬁcantly
to their effects on cancer invasion and metastasis. Knockdown of
PAK1 leads to decreased phosphorylation of myosin light chain in
breast epithelial cells whilst transfection with a plasmid encoding a
mutated inactive PAK1 blocks the invasiveness of breast cancer cells
[42]. Expression of PAK1 increases hepatocyte growth factor-
induced migration of prostate cancer cells [43]. PAKs have also been
implicated in cell adhesion. PAK1 phosphorylates and stimulates the
zinc ﬁnger protein, snail, which in turn represses E-cadherin promot-
er activity, causing cells to detach and migrate [44].
Amongst the six PAK isoforms, the role of PAK1 in human cancer has
beenmost thoroughly investigated. The PAK1 gene is ampliﬁed in blad-
der, ovarian, and breast cancers [45,46]. PAK1 expression is increased in
55% of human breast cancers and overexpression correlates with breast
cancer invasiveness [2]. PAK1 promotes proliferation and survival of
breast cancer cells by activation of nuclear factor kappa B (NFκB) and
cyclin D1, and transgenic mice with a constitutively active PAK1 develop
malignant mammary gland tumours [47]. PAK1 expression also in-
creases with progression through the adenoma to carcinoma sequence
in CRC [48]. PAK1 is critically important for the malignant growth of
both neuroﬁbromatosis types 1 and 2, which are dominantly inherited
autosomal diseases caused by loss-of-function mutations of the tumour
suppressor genes NF1 and NF2, respectively. Mutation carriers are
predisposed to the development of multiple tumours in the central and
peripheral nervous system. Neuroﬁbromin, the product of the NF1
gene, acts as a GTPase-activating protein (GAP) for Ras by accelerating
the intrinsic GTPase activity of Ras, leading to inactivation of Ras and
eventually to inhibition of PAK1 activity. Merlin, the product of the NF2
gene, inhibits PAK1 activation by direct interaction with the Rac-
binding domain of PAK1 [49,50]. Loss of either theNF1 orNF2 gene prod-
uct leads to abnormal activation of PAK1.
The other PAK isoforms may also be up-regulated and/or hyper-
activated in many human cancers, including breast, ovarian, colorectal
and pancreatic cancers [2]. The PAK4 gene is ampliﬁed in colorectal
and pancreatic cancers [51,52]. PAK5 expression is also increased in a
panel of CRC cell lines [53], whilst increased expression of PAK6 has
been detected in both prostate cancer cells and breast tumours [54,55].5. PAKs in gastrointestinal cancers
Gastrointestinal cancer refers to cancers that affect the digestive sys-
tem, and thus includes cancers of the oesophagus, gallbladder, liver,
pancreas, stomach and bowel. Ampliﬁcation of the genes encoding
PAKs and overexpression of PAK proteins have been found in gastroin-
testinal cancers as listed in Table 1 [56]. The importance of PAKs in can-
cers of the liver, pancreas, stomach, colon and rectum will be reviewed
here.Kinase domain
Kinase domain
(PAKs 4–6) are approximately 50% identical. PAKs from both groups also contain a p21
ing motifs for PIX and Nck. For group I PAKs binding of an activated GTPase such as Rac
ges that unfold the AID, which then dissociates from the kinase domain of the other
e kinase domain to be autophosphorylated, which is necessary for full kinase activity
re therefore not shown. The group II PAKs contain an autoinhibitory pseudosubstrate
mational changes in the PSD which lead to increased kinase activity [15,16].
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Hepatocellular carcinoma (HCC) is the most common malignant
primary cancer in the liver. The majority of cases of HCC arise in the
setting of cirrhosis, which may be caused by various factors including
chronic hepatitis B or C infection, or alcohol-induced liver damage.
Hepatocarcinogenesis is a multistep process, associated with changes
in multiple molecular signalling pathways including Wnt/β-catenin
and Ras, and up to 50% of HCC carry mutations in the genes encoding
components of the Wnt/β-catenin pathway [57]. Overexpression of
Ras proteins has been found in cirrhotic livers and inHCC [58], although
Ras mutations are not common in HCC. BRaf and phosphatidylinositol
3-kinase (PI3K) mutations have been also found in HCC patients, and
BRaf mutations are signiﬁcantly correlated with higher proliferation
rates of HCC [59].
PAK1, activated by Ras via PI3K-dependent or independent path-
ways, is overexpressed in HCC patients with more advanced tumours
and more metastatic phenotypes [60]. The PAK1 gene is also ampli-
ﬁed in HCC, and PAK1 stimulates HCC cell migration by activation of
c-Jun NH2-terminal kinase (JNK) and phosphorylation of paxillin. In
humanHCC samples, increased levels of PAK1 correlatedwith poor prog-
nosis, hepatitis B virus (HBV) infection, and portal vein tumour thrombo-
sis [61]. The humanHBVX protein (HBx) is involved in the viral life cycle
and exerts a direct hepatocarcinogenic effect in the development of HCC
[62]. HBx induces mitochondrial translocation of Raf1 kinase by oxida-
tive stress. This mitochondrial translocation of Raf1 is dependent on
the phosphorylation of Raf1 at Ser338/339 and Tyr340/341 by PAK1
and Src kinase, respectively [63]. In HCC cells HBx up-regulates PAK1,
confers resistance to anoikis (a specialised form of apoptosis that occurs
in cells because of inadequate or inappropriate interaction with the cel-
lular matrix), and promotes growth of xenografted tumours in mice.
HBx-induced activation of PAK1 contributes to progression of HCC in pa-
tients with chronic HBV infection.
Currently partial resection or complete resection with liver trans-
plantation offers the only possibility of long-term survival for HCC pa-
tients. In the case of partial resection recurrences occur in more than
two-thirds of these patients. Wang and coworkers have discovered
that early recurrent HCC tumours have signiﬁcantly increased expres-
sion of Rac GTPase-activating protein 1 (RACGAP1) [64]. Although
RACGAP1 overexpression contributes to aggressive recurrence of
HCC [64], inactivation of Rac would be expected to lead to inactiva-
tion of PAK1. Further work will therefore be required to clarify the
possible involvement of PAK1 in HCC recurrence. In this context it is
interesting to note that down-regulation of cyclin D1, associated
with decreased levels of p38 MAP kinase, AKT and PAK1, inhibits pro-
liferation and survival of liver cancer cells [65].
Although PAK1 is clearly involved inmultiple signalling pathways that
signiﬁcantly contribute to the progression of liver cancer, the effects of
othermembers of the PAK family remain to be explored. Recent observa-
tions suggest that the CDK5 kinase regulatory subunit-associated protein
3 (CDK5RAP3) is overexpressed inmore than 50% of HCC specimens, thatTable 1
Genetic alterations of PAKs in gastrointestinal cancers.
Cancer location PAKs Alteration References
Gene ampliﬁcation Protein overexpression
Oesophagus PAK4 ✓ [56]
Liver PAK1 ✓ ✓ [60]
Pancreas PAK1 ✓ [71]
PAK4 ✓ ✓ [51]
Stomach PAK1 ✓ [80,81]
PAK4 ✓ [82,85]
Colon PAK1 ✓ [48]
PAK4 ✓ [52]
PAK5 ✓ [53]CDK5RAP3 binds to and activates PAK4, and that overexpression of
CDK5RAP3 promotes HCC metastasis [66].
5.2. Pancreatic cancer
Pancreatic cancer has the highest mortality rate amongst all carci-
nomas, with an overall 5-year survival rate of less than 5%. The high
mortality has been attributed to the lack of reliable methods for
early detection and to the molecular mechanisms underlying the ag-
gressive pathogenesis [67]. Activating mutations of KRas are amongst
the most common genetic alterations in pancreatic cancer with an in-
cidence of approximately 100% [68,69], and oncogenic Ras activates
both PAK1 and PAK4. PAK4 gene ampliﬁcation is found in pancreatic
cancer, and is associated with signiﬁcantly higher kinase activity of
the PAK4 protein [51]. PAK4 promotes pancreatic cancer cell motility
and invasion [70]. MUC13, a transmembrane mucin, has recently
been found to be overexpressed in pancreatic cancer, and increased
expression of MUC13 in pancreatic cancer cell lines stimulated xeno-
graft growth, and was correlated with increased expression and acti-
vation of PAK1 [71]. Conversely Smad4, which is a tumour suppressor
gene frequently mutated in human pancreatic cancer, induces cell
death by suppression of PAK1 [72]. Although the effect of PAK1 knock-
out on pancreatic tumourigenesis in mice has not been reported, the
importance of PAK1 in pancreatic physiology is highlighted by the ob-
servation that islets from PAK1−/− mice are deﬁcient in the second
sustained phase of insulin secretion [73].
In the past two decades, pancreatic cancer therapy has focussed on
several signalling molecules, with particular interest in membrane re-
ceptors such as the epithelial growth factor receptor (EGFR) [74]. The
EGFR acts, at least in part, thorough Ras, and the outcome of clinical
trials with EGFR inhibitors in pancreatic cancer is dependent on the
mutation status of Ras. A single Kras mutation, which is the most
common genetic alteration in pancreatic cancer, is able to circumvent
the anti-tumour activity of anti-EGFR therapies as mutant forms
of KRas are constitutively active independently of the EGFR. Since on-
cogenic Ras activates PAK1 and PAK4, both of which are overexpressed
and hyper-activated in pancreatic cancer [51,70,71], PAK inhibitors, espe-
cially when combined with classic chemotherapeutic drugs, may provide
a promising therapeutic strategy for pancreatic cancer.
5.3. Gastric cancer
Gastric cancer is one of the most common causes of cancer-related
death. In Asian countries including China, Japan and Korea, the mor-
bidity and mortality of gastric cancer are the highest amongst malig-
nant carcinomas [75]. The majority of gastric cancers in the East Asian
population are associated with infection by virulent strains of the gas-
tric bacterium Helicobacter pylori [76,77]. The strains carry unique
variants of the bacterial protein CagA, which activates PAK1 in host
cells through PIX, a PAK1-activating SH3 adaptor protein (as shown in
Fig. 1). Hence PIX-speciﬁc siRNA blocks the activation of PAK1 by
CagA [77]. Activated PAK1 in turn has been shown to activate NF-κB,
which triggers the release of proinﬂammatory cytokines [78,79].
Both PAK1 and PAK4 are overexpressed in gastric cancer and play
important roles in its metastasis [80–82]. In human gastric cancer cell
lines, PAK1 regulates the expression and activity of cyclins D1 and B1
via NF-κB, and inhibition of PAK1 suppresses proliferation and migra-
tion by decreasing the expression of cyclins D1 and B1 [83,84]. In
gastric cancer patients, overexpression of PAK1 is associated with ad-
vanced and metastatic tumour stages, and increased PAK1 activity is
related to reduced survival [81]. PAK1 affects metastasis of gastric
cancer cells by activation of ERK and JNK [81], whilst PAK4 stimulates
the migration of gastric cancer cells via activation of Lim kinase 1 [85].
Gastric cancer patients with PAK4 overexpression do not respond to
capecitabine/cisplatin treatment and have poor survival [82]. Given























Fig. 2. PAK1 mediates cross-talk between Ras and Wnt/β-catenin signalling in CRC
initiation and progression. Oncogenic Ras activates PAK1, which in turn stimulates
the proliferation, survival, and migration/invasion of CRC cells via activation of ERK-
and AKT-dependent pathways, which are critical for CRC progression. The Wnt-β-catenin
pathway also stimulates CRC cell proliferation andmigration under normoxia, via formation
of a complex between β-catenin and the transcription factor TCF4 in the nucleus. Under
hypoxia, β-catenin interacts with hypoxia-inducible factor 1 (HIF-1) instead, to
stimulate survival and angiogenesis. PAK1 provides a critical connection between
Ras and Wnt-β-catenin pathways by associating with β-catenin and promoting
β-catenin/TCF4 activity.
36 H. He, G.S. Baldwin / Biochimica et Biophysica Acta 1833 (2013) 33–39cells, PAKs are becoming attractive therapeutic targets, especially
since the outcome of current chemotherapy remains disappointing,
with the median survival ranging between 9 and 11 months only
[86].
5.4. Colorectal carcinoma
Colorectal carcinoma (CRC) arises and progresses as a result of cu-
mulative genetic and epigenetic changes in tumour cells. Mutations in
the genes encoding components of the Ras andWnt/β-catenin signal-
ling pathways occur in 50% and 90% of CRCs [87,88]. In animal models
constitutive activation of Wnt/β-catenin signalling initiates growth of
benign adenomas. Mutations in KRas, BRaf and related pathways
stimulate adenoma growth and contribute to invasive and other ma-
lignant behaviours. Despite the high frequency of Wnt/β-catenin mu-
tations in CRC, no therapy targeted to the Wnt pathway has yet been
developed because of the lack of suitable enzyme targets in this path-
way [89].
Activation of KRas by mutation increases cell proliferation and
motility, and KRas mutations are clinically associated with a poor
prognosis of CRC [90]. Ras activates multiple signalling pathways, in-
cluding PAKs, the Raf/MEK/MAPK/ERK cascade and PI3K/AKT [91].
Mutations of KRas, BRaf and PI3K occur in 50%, 10% and 15% of CRC re-
spectively [92]. Whereas KRas mutations do not usually occur in CRC
cells that have BRaf mutations, they may coexist with PI3K mutations
[92]. Because of the inhibitory effects between the PI3K and Raf/MEK/
MARK/ERK pathways [93], blocking one signal alone may increase the
signal from the other pathway. Therefore combined inhibition of both
PI3K and Raf/MEK/MARP/ERK is necessary when considering targeted
therapy.
KRas mutations are often associated with mutations that activate
the Wnt/β-catenin pathway [94]. Synchronous detection of activated
KRas and of nuclear β-catenin, the hallmark of active Wnt signalling,
identiﬁes a group of patients with poor prognosis and resistance to
chemotherapy [95]. Most CRC contain collections of mutations, most
frequently in Ras, Raf, PI3K and components of theWnt/β-catenin sig-
nalling pathway. Although advanced knowledge of the signalling net-
work involved in these pathways has provided useful information for
the development of targeted therapy, the clinical beneﬁts so far have
been limited, indicating a need for improvement in the rational de-
sign of new therapies.
In CRC, expression of PAK1 increases with progression through the
adenoma to carcinoma sequence, with the most dramatic increases in
invasive and metastatic CRC [48]. PAK1 phosphorylates Raf and facil-
itates the Ras/Raf/MAPK signalling pathway which, as mentioned
above, plays a crucial role in CRC development [88,96]. Conversely
PAK1 knockdown downregulates JNK and cyclin D1 [97]. A kinase-
inactive PAK4 blocks oncogenic Ras-induced transformation and in-
hibits the anchorage-independent growth of HCT116 colon cancer
cells [40]. The PAK4 gene is also ampliﬁed in CRC patient samples
[52]. PAK5 is overexpressed during CRC progression and regulates
CRC cell adhesion and migration [53], and apoptosis [31]. The expres-
sion of PAK2 in hepatic stellate cells has been suggested to contribute
to liver metastasis of CRC cells [98].
Recently we have reported that knockdown of PAK1 abrogates
growth and metastasis of CRC cell lines in xenograft and liver metas-
tasis models in mice [99]. PAK1 is also required for the proliferation,
survival, migration, and VEGF secretion of CRC cells harbouring muta-
tions in Ras, PI3K and Apc [100]. Furthermore PAK1 knockdown
inhibited growth, survival and migration of CRC cell lines by inactiva-
tion of ERK and AKT, the downstream targets of Ras [100]. This obser-
vation is consistent with the report by Li and coworkers that PAK1
regulates CRC metastasis through ERK-dependent phosphorylation
of FAK [101]. Interestingly, a recent report has shown that PAK1 is
also required for KRas-driven skin cancer, and that inhibition of
PAK1 causes tumour regression and loss of activity of ERK and AKT[102]. The conclusions of this study are deﬁnitive because the cells
used were derived from PAK−/− mice and hence, although being
more expensive to generate, will not have the off-target effects asso-
ciated with siRNA-treated cells. Taken together, these results indicate
that instead of combination therapies targeting both ERK with a MEK
inhibitor and AKT with a PI3K inhibitor, targeting PAK1 alone could be
an alternative approach in CRC treatment. We have further reported
that PAK1 associates with β-catenin in CRC cells, and that PAK1
knockdown inhibited β-catenin activation by reducing the expression
of β-catenin and c-myc (one of the downstream targets of β-catenin
signalling) and by suppressing β-catenin/TCF4 transcriptional activity
[99]. Consistent with our ﬁndings, Zhu and coworkers have shown
that PAK1 phosphorylated β-catenin at Ser675 leading to a more sta-
ble and transcriptionally active β-catenin in CRC cells [103]. Together
these results indicate that PAK1 is required for β-catenin activation in
CRC and plays a key role in mediating the cross-talk between Ras and
Wnt/β-catenin signalling. However a recent report that PAK1 negative-
ly regulates Wnt signalling in the nematode Caenorhabditis elegans
[104] indicates that PAK1 may act differently in different species.
To summarise, oncogenic Ras activates PAK1, and enhances Wnt/
β-catenin signalling in CRC initiation and progression via activation of
ERK- and AKT-pathways. PAK1 is required for the activation of ERK,
AKT and β-catenin signalling in CRC cells, and is critical for CRC growth
and metastasis in vivo (Fig. 2). These ﬁndings indicate that PAK1 acts as
a convergence point in multiple signalling pathways important for CRC
development.
6. Perspectives in PAK-targeted therapy
The conclusion that PAKs in general, and PAK1 in particular, act as
central nodes in multiple signalling pathways that control cell prolif-
eration, mobility, survival and transformation, makes them attractive
targets in the treatment of diseases including cancers. Functional in-
hibition of PAK1 has been achieved experimentally using several
forms of dominant-negative mutants, RNA interference and a number
of chemical inhibitors with various degrees of speciﬁcity (Table 2).
Several small molecule inhibitors such as CEP-1347, and the SRC and
Table 2
PAK inhibitors.
Inhibitor Kd (nM) Reference
PAK1 PAK4
Competitive with ATP
CEP-1347 >1000 NA [105]
OSU-03012 1000 NA [115]
FL172 110 NA [116]
PF-3758309 14 2.7 [114]
LCH-7749944 NA 15,000 [109]
Not competitive with ATP
WR-PA18 NA NA [110]
IPA3 2500 >10,000 [112]
Mechanism undeﬁned
FRAX597 7.7 >1000 [102]
NA, not available. The recently developed group I-selective inhibitor FRAX597 not only
inhibits PAK1 activity, but also reduces the amount of PAK1 and PAK2 protein in treat-
ed cells and animals [102].
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been shown to inhibit PAK activity [105–107]. The organometallic com-
pound FL172 inhibits PAK1 kinase activity with an IC50 of 110 nM by
blocking the ATP-binding site [108], and LCH-7749944 suppresses
PAK4 kinase activity with an IC50 of 15 μM [109]. The recently devel-
oped group I-selective inhibitor FRAX597 not only inhibits PAK1 activi-
ty, but also reduces the amount of PAK1 and PAK2 protein in treated
cells and animals [102].
Some functions of PAK1 are mediated via kinase-independent,
protein–protein interactions. Targeting short fragments of PAK1 other
than the kinase domain inhibits PAK1 function by blocking its interaction
with other proteins. For example, a small cell-permeable peptide called
WR-PAK18, which includes the PIX-binding site of PAK1, selectively
blocks the PAK–PIX interaction and suppresses Ras transformation in
vitro [110,111]. PAK1 activation has also been suppressed by the alloste-
ric inhibitor IPA-3 [112], which interacts with a domain distinct from the
ATP-binding site. Although IPA-3 showed high potency and selectivity
for group I PAKs, it was not effective against pre-activated group I
kinases.
Although suppression of PAK1 expression by RNAi provides better
discrimination between the individual PAK isoforms, this approach
cannot be used effectively for clinical application because of the insta-
bility of RNAi in vivo. Recently potent pyrroloaminopyrazole-based
PAK inhibitors have been developed by Pﬁzer [113]. The afﬁnity of
PF-3758309 is greatest for PAK4 (Kd=2.7 nM), intermediate for
PAKs 1, 5 and 6 (Kd=14–18 nM), and lowest for PAKs 2 and 3
(Kd=100–190 nM). The observation that PF-3758309 at a daily
oral dose of 20 mg/kg suppressed the growth of several human can-
cers including CRC xenografts in mice [114] suggested that PAK4
might be an attractive therapeutic target in cancer patients. However,
a clinical trial in patients with advanced solid tumours was prema-
turely terminated in 2011 because of “the undesirable PK characteris-
tics of PF-03758309 and the lack of an observed dose–response
relationship” (http://clinicaltrials.gov/show/NCT00932126).
In future efforts to develop PAK inhibitors for cancer therapy, several
potential problems will need to be taken into consideration. Firstly the
inhibitor must overcome the problem of speciﬁcity and redundancy
caused by the diverse and overlapping nature of the PAKs themselves,
and of their regulators and effectors. Secondly inhibitor toxicity caused
by off-target effects must be low. Thirdly the development of acquired
resistance to PAK inhibitor therapy must be limited. With increasing
knowledge of PAK signalling in normal and cancer cells, the develop-
ment of PAK inhibitors should further elucidate the role of PAKs in
tumourigenesis and help to establish the PAK family as targets for clin-
ical therapy.References
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